The90-day Prognostic Evaluation Value Of Copeptin In Patients With Acute Decompensated Heart Failure

AimsThis study investigated the prognostic evaluation value of a marker,C-terminal part of the arginine vasopressin prohormone (Copeptin) inpatients with acute decompensated heart failure.MethodsWe conducted a prospective, observational cohort study in a tertiarycare hospital and enrolled129patients with acute decompensated heartfailure. Clinicians were blinded to investigational markers exceptNT-proBNP, and the study participants were followed for90-day. The endpoint was a composite of cardiovascular death or re-hospitalization due todecompensated heart failure. The prognostic evaluation value wascompared between copeptin and NT-proBNP.ResultsOf the129patients enrolled,47reached end point and82in stablecondition during follow-up. Receiver operating characteristic curve (ROC)curve analysis showed that the areas under curve (AUCs) for the prediction of90-day adverse events were similar for copeptin0.602(SE，0.052；95%CI0.499-0.705), NT-proBNP0.659(SE，0.048；95%CI0.565-0.753) andtheir combination0.670(SE，0.050；95%CI0.573-0.767).ConclusionsThe study provides evidence that copeptin measurements havepredictive properties for adverse events in acute decompensated heartfailure, and copeptin may provide the same90-day prediction compared toNT-proBNP. Combination of the two markers can not improve theprognostic evaluation of patients with acute decompensated heart failure.